ResMed (RMD)
(Delayed Data from NYSE)
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum A VGM
Zacks News
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 6.90% and 3.63%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Medical Products' Oct 24 Earnings Roster: BAX, CERN & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Should You Buy ResMed (RMD) Ahead of Earnings?
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask
by Zacks Equity Research
ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sleep Apnea Market Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.
GNNDY or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GNNDY vs. RMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors' confidence continues to be high on ResMed's (RMD) prospects.
ResMed (RMD) Up 6.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.
NUVA vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
Analysts Estimate ResMed (RMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
by Zacks Equity Research
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
Add These 5 Stocks With Solid Sales Growth to Your Portfolio
by Swayta Shah
Consistent growth in sales is the key to survival for any business.
ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite
by Zacks Equity Research
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
ResMed (RMD) Up 7.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.